Novel non-FDG radiotracers targeting diverse inflammatory pathways may offer enhanced specificity over FDG-PET for imaging and quantifying disease activity in myocardial inflammatory diseases.
Do novel non-FDG radiotracers provide better specificity and quantification of myocardial inflammation compared to FDG-PET in patients with inflammatory cardiac diseases?
Novel non-FDG radiotracers offer the potential for more specific imaging of myocardial inflammation, overcoming the limitations of physiological uptake seen with FDG-PET.
Myocardial inflammation plays a central role in the pathophysiology of various cardiac diseases. While FDG-PET is currently the primary method for molecular imaging of myocardial inflammation, its effectiveness is hindered by physiological myocardial uptake as well as its propensity for uptake by multiple disease-specific mechanisms. Novel radiotracers targeting diverse inflammatory immune cells and molecular pathways may provide unique insight through the visualization of underlying mechanisms central to the pathogenesis of inflammatory cardiac diseases, offering opportunities for increased understanding of immunocardiology. Moreover, the potentially enhanced specificity may lead to better quantification of disease activity, aiding in the guidance and monitoring of immunomodulatory therapy. This review aims to provide an update on advancements in non-FDG radiotracers for imaging myocardial inflammatory diseases, with a focus on cardiac sarcoidosis, myocarditis, and acute myocardial infarction.
Lucinian et al. (Fri,) conducted a review in Myocardial inflammatory diseases. Non-FDG radiotracers vs. FDG-PET was evaluated. Novel non-FDG radiotracers targeting diverse inflammatory pathways may offer enhanced specificity over FDG-PET for imaging and quantifying disease activity in myocardial inflammatory diseases.